This prospective observational study was performed from October 2015 to January 2017. The study protocol was approved by the Ethics Committee at Wenzhou Medical University and complied with the tenets of the Declaration of Helsinki. Informed consent was obtained from all patients and subjects before imaging. The inclusion criteria for the BD groups were fulfillment of the diagnostic criteria developed by the International Study Group for Behçet's Disease,
24 BD in remission,
18 and evidence of posterior segment involvement.
25,26 Exclusion criteria for eyes with BD were anterior uveitis only, a spherical equivalent refractive error greater than ±6.0 diopters, significant cataract or vitreous opacity, diabetic retinopathy, age-related macular degeneration, glaucoma, other marked complications, or a history of intraocular surgery within the previous year. We selected the eye with higher signal-strength index in patients with bilateral Behçet's uveitis. Normal subjects with no history of systemic disease and matched for age, sex, and spherical equivalent were recruited as controls. The right eye of each subject was selected. The exclusion criteria for the control group were ocular disease (e.g., diabetes retinopathy or glaucoma), best-corrected visual acuity (BCVA) <20/20, and a spherical equivalent refractive error more than ±6.0 diopters.
We divided the patients with BD into two groups according to the number of ocular attacks (n < 5 or n ≥ 5). Each patient underwent a complete ocular examination, including slit-lamp examination, intraocular pressure measurement (Goldman applanation tonometry), funduscopy, FA, and OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany) and OCTA (AngioVue; Optovue, Inc., Fremont, CA, USA). Demographic and clinical data were collected, including for sex, age, interval between the last ocular attack and the current remission phase, duration of Behçet's uveitis, and number of attacks. All patients were examined by the same uveitis specialist. Mydriasis was obtained by applying eyedrops containing 0.5% tropicamide and 0.5% phenylephrine hydrochloride to both eyes at least 30 minutes before imaging. The spherical equivalent refractive error of each eye was measured using an autorefractor (KR8900; Topcon, Tokyo, Japan). BCVA was measured using a Snellen chart and converted to logarithm of the minimum angle of resolution (logMAR) units for analysis.